ARP Americas LP increased its position in Omnicell, Inc. (NASDAQ:OMCL) by 34.5% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 5,247 shares of the company’s stock after purchasing an additional 1,346 shares during the period. ARP Americas LP’s holdings in Omnicell were worth $371,000 at the end of the most recent reporting period.
A number of other institutional investors have also recently made changes to their positions in the stock. Duality Advisers LP bought a new position in Omnicell in the 2nd quarter worth about $1,801,000. Raymond James & Associates lifted its stake in Omnicell by 431.0% during the 2nd quarter. Raymond James & Associates now owns 64,179 shares of the company’s stock valued at $4,532,000 after acquiring an additional 52,092 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in Omnicell by 42.2% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 4,485 shares of the company’s stock valued at $317,000 after acquiring an additional 1,330 shares during the period. Vident Investment Advisory LLC lifted its stake in Omnicell by 42.0% during the 2nd quarter. Vident Investment Advisory LLC now owns 179,555 shares of the company’s stock valued at $12,680,000 after acquiring an additional 53,099 shares during the period. Finally, Strs Ohio lifted its stake in Omnicell by 22.9% during the 2nd quarter. Strs Ohio now owns 63,400 shares of the company’s stock valued at $4,477,000 after acquiring an additional 11,800 shares during the period. Institutional investors own 95.79% of the company’s stock.
Shares of NASDAQ OMCL traded down $1.04 during midday trading on Friday, hitting $70.29. 286,300 shares of the company’s stock traded hands, compared to its average volume of 286,808. The firm has a fifty day moving average of $67.18 and a 200 day moving average of $72.69. The stock has a market capitalization of $3.00 billion, a price-to-earnings ratio of 62.20, a price-to-earnings-growth ratio of 2.78 and a beta of 1.03. Omnicell, Inc. has a 1 year low of $54.24 and a 1 year high of $94.85.
Omnicell (NASDAQ:OMCL) last released its earnings results on Tuesday, July 28th. The company reported $0.37 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.23 by $0.14. The company had revenue of $199.62 million during the quarter, compared to analyst estimates of $182.16 million. Omnicell had a net margin of 5.42% and a return on equity of 9.21%. The firm’s quarterly revenue was down 8.2% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.67 EPS. On average, analysts predict that Omnicell, Inc. will post 1.68 EPS for the current year.
In related news, CEO Randall A. Lipps sold 3,718 shares of the stock in a transaction that occurred on Wednesday, July 29th. The shares were sold at an average price of $75.15, for a total value of $279,407.70. Following the completion of the sale, the chief executive officer now directly owns 152,116 shares of the company’s stock, valued at approximately $11,431,517.40. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Scott Peter Seidelmann sold 2,125 shares of the stock in a transaction that occurred on Tuesday, June 16th. The stock was sold at an average price of $67.70, for a total transaction of $143,862.50. Following the completion of the sale, the executive vice president now directly owns 33,385 shares of the company’s stock, valued at $2,260,164.50. The disclosure for this sale can be found here. Corporate insiders own 2.63% of the company’s stock.
Several equities analysts have issued reports on the stock. Piper Sandler lowered their target price on shares of Omnicell from $76.00 to $70.00 and set a “neutral” rating on the stock in a research note on Wednesday. ValuEngine cut shares of Omnicell from a “buy” rating to a “hold” rating in a research note on Friday, April 17th. Craig Hallum lowered their target price on shares of Omnicell from $102.00 to $85.00 and set a “buy” rating on the stock in a research note on Wednesday. Cantor Fitzgerald upped their target price on shares of Omnicell from $85.00 to $90.00 and gave the company an “overweight” rating in a research note on Wednesday. Finally, Stephens assumed coverage on shares of Omnicell in a research report on Monday, July 6th. They set an “overweight” rating and a $90.00 price target for the company. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and five have assigned a buy rating to the company. Omnicell currently has a consensus rating of “Hold” and an average target price of $85.50.
Omnicell Company Profile
Omnicell, Inc provides medication and supply dispensing automation, central pharmacy automation, analytics software, and medication adherence solutions for the healthcare industry worldwide. It operates in two segments, Automation and Analytics, and Medication Adherence. The Automation and Analytics segment offers central pharmacy automation solutions, including automated storage and retrieval systems, such as XR2 Automated Central Pharmacy System, a building block of autonomous pharmacy vision; IV compounding robots and workflow management systems; inventory management software; and controlled substance management systems.
Read More: What is the market perform rating?
Want to see what other hedge funds are holding OMCL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Omnicell, Inc. (NASDAQ:OMCL).
Receive News & Ratings for Omnicell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell and related companies with MarketBeat.com's FREE daily email newsletter.